secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2026-06-26T21:15:40+00:00
Accession:  0001493152-26-030342
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma receives NYSE American non-compliance notice; granted plan period through Oct 2027
--------------------------------------------------------------------------------

- Stockholders' equity of $3.02M as of March 31, 2026 fails the $4M minimum under Section 1003(a)(ii) of NYSE American Guide.
- Company also continues to be non-compliant with the $6M equity standard under Section 1003(a)(iii) as previously disclosed.
- NYSE American accepted the Company's plan to regain compliance, granting a plan period through October 2, 2027.
- Common stock will continue trading on NYSE American under symbol MTNB during the plan period; delisting proceedings possible if not compliant by deadline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226030342/0001493152-26-030342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226030342/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-030342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer